

**Methylprednisolone/tozinameran****S****Multiple sclerosis and lack of efficacy: case report**

A 28-year-old woman developed relapsing multiple sclerosis (MS) following tozinameran vaccination. Additionally, she exhibited lack of efficacy during treatment with methylprednisolone [*not all routes and dosages stated*].

The woman, had received tozinameran vaccine [BNT162b2, Comirnaty®, BioNTech/Pfizer] for Covid-19 prophylaxis. However, 6 days post well-tolerated vaccination, she developed sensory impairment below the T6 level, left abdominal neuropathic pain, hypoesthesia of genital regions and right abdominal wall and left leg paresis. MRI-spinal cord on day 18 post vaccination was suggestive of myelitis; whereas, cerebral MRI revealed multiple, partially confluent lesions. CSF analysis showed mild pleocytosis. She was found to be SARS-CoV-2 negative. Therefore, she was diagnosed with relapsing MS attributed to the tozinameran vaccine, depending upon 2017 McDonald criteria.

The woman, started receiving therapy with IV methylprednisolone 1000 mg for 5 days. Thereafter, in spite of receiving second cycle of IV methylprednisolone 2000 mg for 5 days, her symptoms did not improve (lack of efficacy). Hence, currently, she received plasma exchange therapy, which further improved her condition.

Havla J, et al. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. *Journal of Neurology* 269: 55-58, No. 1, Jan 2022.  
Available from: URL: <https://link.springer.com/journal/415>

803645191